NCT01595295 is a clinical trial of non interventional in Chronic Myelomonocytic Leukemia, sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie.

Who is sponsoring NCT01595295?

NCT01595295 is sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie.

What drugs are being tested in NCT01595295?

Interventions in NCT01595295: non interventional.

What condition does NCT01595295 study?

NCT01595295 studies Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Acute Myeloid Leukemia.

Is NCT01595295 still recruiting?

NCT01595295 is currently completed. Last updated 25 March 2024.

Last reviewed 2024-03-25 · How we verify

NCT01595295

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Registry on Hypomethylating Agents in Myeloid Neoplasms

Completed Last updated 25 March 2024

What this trial tests

trial testing non interventional in Chronic Myelomonocytic Leukemia in 1,500 participants. Completed in 31 December 2021.

Timeline

9 February 2009

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Arbeitsgemeinschaft medikamentoese Tumortherapie
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,500
Start date	9 February 2009
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	20 locations across Austria, Croatia

Drugs / interventions tested

non interventional

Conditions studied

Chronic Myelomonocytic Leukemia — all drugs for Chronic Myelomonocytic Leukemia →
Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →
Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →

Sponsor

Arbeitsgemeinschaft medikamentoese Tumortherapie — full company profile →

Who can join

18 and older, any sex, with Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This registry is set up to collect real-world experience in the management of patients with myeloid neoplasms, in particularly in patients with MDS, CMML or AML, treated with hypomethylating agents in Austria and potentially other participating countries. This registry will collect data in a retrospective as well as in a prospective manner at various sites. The aim is to gain valuable insights on both efficacy and toxicity of these drugs in a routine clinical setting in patients with various comorbidities.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.
Pleyer L, Burgstaller S, Girschikofsky M, Linkesch W, et al · · 2014 · cited 73× · PMID 24951123 · DOI 10.1007/s00277-014-2126-9
Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group.
Pleyer L, Stauder R, Burgstaller S, Schreder M, et al · · 2013 · cited 51× · PMID 23627920 · DOI 10.1186/1756-8722-6-32
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
Pleyer L, Döhner H, Dombret H, Seymour JF, et al · · 2017 · cited 42× · PMID 28212292 · DOI 10.3390/ijms18020415
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, et al · · 2016 · cited 31× · PMID 27084507 · DOI 10.1186/s13045-016-0263-4
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT.
Pleyer L, Heibl S, Tinchon C, Vallet S, et al · · 2023 · cited 10× · PMID 36900181 · DOI 10.3390/cancers15051388
Hypomethylating agent-based therapies in older adults with acute myeloid leukemia - A joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee.
Neuendorff NR, Gagelmann N, Singhal S, Meckstroth S, et al · · 2023 · cited 9× · PMID 36435726 · DOI 10.1016/j.jgo.2022.11.005
Scalable Enrichment of Immunomodulatory Human Acute Myeloid Leukemia Cell Line-Derived Extracellular Vesicles.
Binder HM, Maeding N, Wolf M, Cronemberger Andrade A, et al · · 2021 · cited 7× · PMID 34943829 · DOI 10.3390/cells10123321
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group.
Leisch M, Pfeilstöcker M, Stauder R, Heibl S, et al · · 2022 · cited 5× · PMID 35626063 · DOI 10.3390/cancers14102459

Verify or expand the search:

Other trials of non interventional

Trials testing the same drug.

NCT05362123 — Survey on the Effectiveness of the PLAB Examination in Continuing Clinical Education in British Doctors. · completed
NCT05116956 — SKin and Soft Tissue Necrotizing INfections in the Intensive Care Unit: a Prospective Multi-national Cohort Study · unknown
NCT04406363 — Confinement Effect on Low Back Pain Intensity in Chronic Low Back Pain Patients · unknown
NCT04068363 — Donor Gender Effect on Graft Function in Adult Egyptian Patients Undergoing Living Donor Liver Transplant · completed
NCT06222905 — Analysis of Remote Monitoring/Virtual Clinic Data in Adult Patients With Cystic Fibrosis (Project Breathe) · active not recruiting

Other recruiting trials for Chronic Myelomonocytic Leukemia

Currently open trials in the same condition.

NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease ( · Phase 2 · recruiting
NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting
NCT07046078 — Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hem · Phase 2 · recruiting
NCT06630221 — Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations · Phase 2 · recruiting
NCT06815003 — Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Di · Phase 2 · recruiting

Other Arbeitsgemeinschaft medikamentoese Tumortherapie trials

Trials by the same sponsor.

NCT06294652 — AGMT Austrian Lymphoma Registry · recruiting
NCT06250465 — AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry · recruiting
NCT03984214 — Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Panc · Phase 3 · completed
NCT03792763 — Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients · Phase 2 · completed
NCT03301493 — Genomic Testing and Resulting Medical Decisions · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01595295 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arbeitsgemeinschaft medikamentoese Tumortherapie
Last refreshed: 25 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01595295.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing